AT420660T - ANTIBODIES DIRECTED TO PARATHYROID HORMONE (PTH) AND USES THEREOF

24 members in 14 offices

This recordMember, by publication datePriority claim4 more offices are in the list below

Priority claims
Document	Office	Kind	Date
0325161	United States of America	W	2003-08-08

Family members, oldest first
Document	Office	Kind
US2005031614A1	United States of America	A1	2005-02-10
CA2535156A1	Canada	A1	2005-02-24
WO2005016111A2	World Intellectual Property Organization (WIPO)	A2	2005-02-24
AU2003282780A1	Australia	A1	2005-03-07
WO2005016111A9	World Intellectual Property Organization (WIPO)	A9	2005-05-19
US2006062783A1	United States of America	A1	2006-03-23
WO2006039258A2	World Intellectual Property Organization (WIPO)	A2	2006-04-13
MXPA06001353A	Mexico	A	2006-05-04
WO2005016111A3	World Intellectual Property Organization (WIPO)	A3	2006-05-04
NO20061070L	Norway	L	2006-05-05
EP1659918A2	European Patent Office (EPO)	A2	2006-05-31
IL173323A0	Israel	A0	2006-06-11
BR0318454A	Brazil	A	2006-09-12
WO2006039258A3	World Intellectual Property Organization (WIPO)	A3	2006-09-14
CN1838968A	China	A	2006-09-27
EP1659918A4	European Patent Office (EPO)	A4	2007-05-02
JP2007521232A	Japan	A	2007-08-02
US7288253B2	United States of America	B2	2007-10-30
US7318925B2	United States of America	B2	2008-01-15
EP1659918B1	European Patent Office (EPO)	B1	2009-01-14
AT420660TThis record	Austria	T	2009-01-15
ATE420660T1	Austria	T1	2009-01-15
DE60325906D1	Germany	D1	2009-03-05
ES2321088T3	Spain	T3	2009-06-02

1 legal event, as the office reported them to INPADOC

Legal events, newest first
	Event	Code
2009-07-15	Ceased as to paragraph 5 lit. 3 law introducing patent treatiesCeasedRER	RER

CPC, 10: C07K16/26
A01K2217/075
A61K2039/505
C07K2317/21
C07K2317/92
C07K2317/34
C07K2317/76
A61P5/16
A61P5/18
A61P5/20
Filled: the office’s first classification
IPC, 5: A61K39 395
A61P5 20
C07K14 635
C07K16 26
C12N15 13

Antibodies directed to parathyroid hormone (pth) and uses thereof